Cannabigerol for Post-Surgery Recovery After Bladder Cancer Surgery
This study is looking at how safe and tolerable a supplement called cannabigerol is for people having surgery for non-metastatic bladder cancer. Cannabigerol is given as chewable gummies. You would take these gummies for one month after surgery, with a two-week period before surgery to adjust the dose. The study wants to see if taking cannabigerol helps with symptoms and improves your quality of life after a radical cystectomy (surgery to remove the bladder) and urinary diversion (creating a new way for urine to leave the body). To join, you must be 18 or older, have non-metastatic bladder cancer, be scheduled for this surgery, and live in California. The study is currently unclear on its recruitment status and plans to enroll 20 participants.
- Study design
- This is an open-label, single-group study, meaning everyone receives the cannabigerol gummies and you and the researchers will know what treatment you are getting. It is a pilot study with 20 participants.
- What's involved
- You would take cannabigerol gummies for a total of about six weeks: two weeks before your surgery and one month after your surgery.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety and side effects will be monitored from when you start treatment until one month after treatment ends.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy
At a glance
Conditions
NCT07577999
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Stanford University
Palo Alto, Californiastudy coordinator listed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Jay Shah, MD · PRINCIPAL_INVESTIGATOR · Stanford University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Grade ≥2 Adverse Events and Dose-Limiting ToxicitiesFrom treatment initiation through 1 month post-treatment (including 2-week lead-in period)
Assessment of safety and tolerability of hemp-derived cannabigerol gummies based on the incidence of Grade ≥2 adverse events (AEs) that are unresponsive to dose reduction or medical management. AEs of interest include tachycardia, xerostomia, dizziness, nausea, anxiety/depression, euphoria/impairment, fatigue, and memory impairment. Tolerability will also be evaluated by the frequency of: Dose reductions Treatment discontinuations Patient-reported tolerability (including taste, texture, and overall acceptability) All AEs will be graded using standard toxicity criteria and recorded throughout the study. Dose adjustments and discontinuations will be documented and attributed to treatment.